Frontiers in Immunology

dc.creatorMaggi, Jaxaira
dc.creatorSchinnerling, Katina
dc.creatorPesce, Barbara
dc.creatorHilkens, Catharien M
dc.creatorCatalán, Diego Francisco
dc.creatorAguillón-Gutiérrez, Juan Carlos
dc.date2018-11-29T15:36:51Z
dc.date2022-07-07T15:55:28Z
dc.date2014
dc.date2018-11-29T15:36:51Z
dc.date2022-07-07T15:55:28Z
dc.date2016
dc.date.accessioned2023-08-22T22:32:51Z
dc.date.available2023-08-22T22:32:51Z
dc.identifier1140553
dc.identifier1140553
dc.identifierhttps://hdl.handle.net/10533/228542
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8347396
dc.descriptionTolerogenic dendritic cells (DCs) are a promising tool to control T cell-mediated autoimmunity. Here, we evaluate the ability of dexamethasone-modulated and monophosphoryl lipid A (MPLA)-activated DCs [MPLA-tolerogenic DCs (tDCs)] to exert immunomodulato
dc.descriptionRegular
dc.descriptionFONDECYT
dc.descriptionFONDECYT
dc.languageeng
dc.relationhandle/10533/111556
dc.relationhandle/10533/111541
dc.relationhandle/10533/108045
dc.relationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027201/
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleDexamethasone and monophosphoryl lipid a-modulated dendritic cells promote antigen-specific tolerogenic properties on naive and memory cd4+ t cells.
dc.titleFrontiers in Immunology
dc.typeArticulo
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución